Comparative Pharmacology
Head-to-head clinical analysis: CAMPATH versus PRALATREXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMPATH versus PRALATREXATE.
CAMPATH vs PRALATREXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
Folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis and cell proliferation.
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
30 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Clinical Note
moderatePralatrexate + Digoxin
"Pralatrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePralatrexate + Digitoxin
"Pralatrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePralatrexate + Deslanoside
"Pralatrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePralatrexate + Acetyldigitoxin
"Pralatrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
Terminal elimination half-life is approximately 12–19 hours in patients with normal renal function, supporting a weekly dosing interval.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Renal excretion accounts for approximately 70-80% of the administered dose as unchanged drug; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Monoclonal Antibody, Antineoplastic
Antineoplastic